Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection
- PMID: 17458776
- DOI: 10.1055/s-2007-976494
Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection
Abstract
Infection is the leading cause of morbidity and mortality in immunocompromised patients such as hematopoietic/solid organ transplant recipients and individuals with human immunodeficiency virus. Community respiratory virus infections are increasingly recognized as a significant threat to these patients. This article reviews current information in the clinical field of community respiratory viruses, including several newly discovered respiratory viruses. Respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses cause the most serious disease in immunocompromised hosts, but other respiratory viruses are becoming increasingly appreciated as a cause of both upper and lower respiratory tract disease. The clinical impact of these new viruses, including human metapneumovirus, non-SARS human coronaviruses, and human bocavirus, is not yet clear. Modern molecular technology has made the discovery of new viruses possible; the use of these new technologies in direct patient care is not yet standard but is becoming increasingly utilized. Clinicians should appreciate the potential for the development of antiviral resistance to influenza antivirals in immunocompromised patients.
Similar articles
-
Respiratory viral infections in transplant recipients.Antivir Ther. 2007;12(4 Pt B):627-38. Antivir Ther. 2007. PMID: 17944270 Review.
-
Community acquired respiratory and gastrointestinal viral infections: challenges in the immunocompromised host.Curr Opin Infect Dis. 2012 Aug;25(4):423-30. doi: 10.1097/QCO.0b013e328355660b. Curr Opin Infect Dis. 2012. PMID: 22766648 Review.
-
Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia.Semin Hematol. 2009 Jul;46(3):230-47. doi: 10.1053/j.seminhematol.2009.03.004. Semin Hematol. 2009. PMID: 19549576 Review.
-
Antiviral therapy of respiratory viruses in haematopoietic stem cell transplant recipients.Antivir Ther. 2012;17(1 Pt B):175-91. doi: 10.3851/IMP2060. Epub 2012 Feb 3. Antivir Ther. 2012. PMID: 22311587 Review.
-
Viral infections in transplant recipients.Minerva Med. 2009 Dec;100(6):479-501. Minerva Med. 2009. PMID: 20010483 Review.
Cited by
-
Update in Viral Infections in the Intensive Care Unit.Front Med (Lausanne). 2021 Feb 23;8:575580. doi: 10.3389/fmed.2021.575580. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33708775 Free PMC article. Review.
-
Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.Clin Infect Dis. 2016 Oct 15;63(8):999-1006. doi: 10.1093/cid/ciw451. Epub 2016 Aug 1. Clin Infect Dis. 2016. PMID: 27481873 Free PMC article.
-
Coagulation factor X activates innate immunity to human species C adenovirus.Science. 2012 Nov 9;338(6108):795-8. doi: 10.1126/science.1226625. Epub 2012 Sep 27. Science. 2012. PMID: 23019612 Free PMC article.
-
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.Clin Infect Dis. 2020 Dec 31;71(11):2777-2786. doi: 10.1093/cid/ciz1166. Clin Infect Dis. 2020. PMID: 31793991 Free PMC article. Clinical Trial.
-
Human Adenovirus Associated Hepatic Injury.Front Public Health. 2022 Apr 28;10:878161. doi: 10.3389/fpubh.2022.878161. eCollection 2022. Front Public Health. 2022. PMID: 35570934 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous